C
CeQur
Health Tech & Medtech · Horw, Switzerland · Founded 2008
Developing and commercializing simple drug delivery devices that can be easily integrated into daily life MoreLess
CeQur Simplicity is a medical device company specializing in innovative insulin delivery systems designed to improve diabetes management. The company serves individuals with diabetes who require mealtime insulin, offering a discreet, compact, and water-resistant patch that simplifies insulin administration. Operating in the healthcare and medical device market, CeQur Simplicity's business model revolves around the sale of its proprietary insulin delivery patches. Revenue is generated through direct sales to consumers and partnerships with healthcare providers. The product is clinically proven to reduce A1C levels and increase Time in Range (TIR), thereby minimizing long-term health complications associated with diabetes. The patch stays in place for up to three days, allowing users to maintain their insulin regimen with less interference and added convenience. CeQur Simplicity aims to ease the burden of multiple daily injections, replacing them with a single patch that delivers rapid-acting insulin with just one click. The company focuses on providing a user-friendly solution that enhances adherence to insulin therapy, ultimately improving patient outcomes.
Keywords: insulin delivery, diabetes management, medical device, A1C reduction, Time in Range, discreet patch, water-resistant, healthcare, patient adherence, mealtime insulin.
Company overview
CeQur company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2008
- Headquarters
- Horw, Switzerland
- Employees
- 150
- Open positions
- None listed
- Dealroom signal
- 90.5
Valuation & funding
CeQur funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES EOther financing | Jun 2026 | $100M | $600M | Undisclosed | ↗ |
| LATE VCOther financing | Jan 2025 | $120M | $480M | Undisclosed | ↗ |
| SERIES COther financing | Apr 2021 | $115M | $460M | Tandem Diabetes Care · Federated Hermes · Ypsomed · GMS Capital | — |
| SERIES COther financing | Sep 2015 | $100M | $400M | Schroders · Endeavour Vision · Woodford Investment Management · Arthurian Life Sciences | — |
| SERIES BOther financing | Sep 2013 | $27M | $108M | Undisclosed | — |
| SERIES AOther financing | Jan 2010 | VI Partners · Schroders · Endeavour Vision | — | ||
| CORPORATE SPINOUTOther financing | Dec 2008 | Danfoss | ↗ |
Growth signals
CeQur website traffic
Latest recorded traffic for CeQur is 25K monthly website visits, down 35.9% over the last three months. CeQur's team grew 13.6% over the past year.
Comparisons
CeQur compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
CeQur's talent
Source: Dealroom Talent Intelligence.
Investors
12 investors on CeQur's cap table
Sourced from Dealroom's funding and investor records.











Global footprint
Where CeQur has talent and traffic
team presence
In the news
Latest news about CeQur
Recent press, funding announcements, and product moves mentioning CeQur — open to read from the original sources.
Market sentiment
What the market is saying about CeQur
An AI-synthesized read of the highest-engagement posts about CeQur on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CeQur’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







